Diagnosis criteria for hypertension

Reading File

Finding Sources

Searching PubMed

"hypertension" AND "diagnostic criteria"

Searching the Web

hypertension diagnosis criteria 2024 guidelines ACC AHA JNC

Finding Sources

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC12995957

Reading File

Finding Sources

Reading File

I now have excellent, comprehensive data to answer this question. Let me compile it all.

Diagnosis Criteria for Hypertension

1. ACC/AHA Classification (USA - 2017, reaffirmed 2025)

This is the most widely used classification for adults (≥18 years):

BP Category	Systolic BP (mmHg)		Diastolic BP (mmHg)
Normal	<120	and	<80
Elevated	120-129	and	<80
Stage 1 Hypertension	130-139	or	80-89
Stage 2 Hypertension	≥140	or	≥90

If systolic and diastolic readings fall in different categories, use the higher classification.

Diagnosis requires an average of ≥2 readings on ≥2 separate occasions.

Patients on antihypertensive medication are classified as hypertensive regardless of current BP.

- Harrison's Principles of Internal Medicine 22E, Table 288-1; Fuster and Hurst's The Heart 15th Ed, Table 5-1

2. ESC/ESH Classification (Europe - 2023/2024)

The European guidelines retain the traditional ≥140/90 mmHg threshold for diagnosis and use a grade-based system:

Category	Systolic (mmHg)		Diastolic (mmHg)
Optimal	<120	and	<80
Normal	120-129	and/or	80-84
High Normal	130-139	and/or	85-89
Grade 1 Hypertension	140-159	and/or	90-99
Grade 2 Hypertension	160-179	and/or	100-109
Grade 3 Hypertension	≥180	and/or	≥110

- Comprehensive Clinical Nephrology 7th Ed, Table 34.3

3. Out-of-Office BP Thresholds for Hypertension Diagnosis

Office BP alone can miss white-coat and masked hypertension. Both ACC/AHA and ESC guidelines now incorporate out-of-office monitoring:

Measurement Type	Threshold for Hypertension
Office/Clinic BP	≥140 and/or ≥90 mmHg
24-hour ambulatory (mean)	≥130 and/or ≥80 mmHg
Daytime (awake) ambulatory	≥135 and/or ≥85 mmHg
Nighttime (asleep) ambulatory	≥120 and/or ≥70 mmHg
Home BP monitoring (HBPM)	≥135 and/or ≥85 mmHg

- Comprehensive Clinical Nephrology 7th Ed; 2025 AHA/ACC Guideline

4. Hypertension in Children and Adolescents

Children 1-12 years: Hypertension = BP at or above the 95th percentile (age-, sex-, and height-specific norms), or SBP ≥130 or DBP ≥80 mmHg
Adolescents ≥13 years: Same criteria as adults (≥130/80 for Stage 1, ≥140/90 for Stage 2)
Elevated BP in children: ≥90th percentile to <95th percentile, or ≥120/80 to <95th percentile

- Fuster and Hurst's The Heart 15th Ed; Harrison's 22E

5. Special Situations

Hypertension in Pregnancy (ACOG criteria):

Hypertension: SBP ≥140 mmHg and/or DBP ≥90 mmHg
Severe hypertension (in preeclampsia): SBP ≥160 mmHg or DBP ≥110 mmHg on two occasions ≥4 hours apart

Hypertensive Urgency/Emergency (Stage 2 severe): SBP ≥180 and/or DBP ≥120 mmHg with or without target organ damage

6. Key Diagnostic Points (2025 AHA/ACC Guideline Updates)

The 2025 AHA/ACC Guideline (which replaces the 2017 version) introduced several updates:

Home BP monitoring (HBPM) and ambulatory BP monitoring (ABPM) are now central to confirming diagnosis - not just supplementary
White-coat hypertension (elevated office BP, normal out-of-office BP) must be excluded before initiating therapy
Masked hypertension (normal office BP, elevated out-of-office BP) must be detected to avoid undertreatment
Risk stratification now uses the PREVENT calculator for 10- and 30-year total CVD risk, replacing the older Pooled Cohort Equations
Primary aldosteronism screening is now recommended for all patients with Stage 2 or resistant hypertension, regardless of potassium level

Summary: Key Threshold Comparison

Guideline	Hypertension Threshold
ACC/AHA 2017/2025 (USA)	≥130/80 mmHg (Stage 1)
ESC/ESH 2023/2024 (Europe)	≥140/90 mmHg (Grade 1)
JNC 7 (older)	≥140/90 mmHg

The ACC/AHA threshold of ≥130/80 remains controversial - the European and most international guidelines still use ≥140/90 as the cutoff for defining hypertension, though they classify 130-139/85-89 as "high normal" which warrants close monitoring and lifestyle intervention.

Amlodipine + valsartan

Reading File

Finding Sources

Searching PubMed

"amlodipine" AND "valsartan" AND "hypertension"

Searching the Web

amlodipine valsartan combination therapy hypertension mechanism clinical evidence

Reading File

Finding Sources

Reading File

I now have comprehensive information from multiple authoritative textbooks. Let me compile a thorough answer.

Amlodipine + Valsartan Combination

This is a well-established fixed-dose combination (FDC) marketed as Exforge, pairing a dihydropyridine calcium channel blocker (CCB) with an angiotensin receptor blocker (ARB). The two drugs work through complementary and partially synergistic mechanisms.

Individual Drug Profiles

Amlodipine (CCB - Dihydropyridine)

Mechanism: Blocks L-type voltage-gated calcium channels in vascular smooth muscle, causing peripheral arterial vasodilation. Unlike non-dihydropyridines (verapamil, diltiazem), it has minimal cardiac effects (no significant negative chronotropy/inotropy) and does not slow AV conduction. It binds to both dihydropyridine and non-dihydropyridine receptor sites, producing vasodilation without significant sympathetic nervous system activation.

Pharmacokinetics:

Almost complete oral absorption; peak plasma levels at 6-12 hours
Half-life: 30-50 hours (uniquely long among CCBs; prolonged further in elderly)
No sustained-release formulation needed - once-daily dosing
90% hepatic metabolism, 10% excreted unchanged; no dose adjustment needed in renal impairment
Antihypertensive effect may persist up to 5 days after discontinuation

Dosing: 2.5 mg (starting dose, especially elderly) to 10 mg once daily

- Brenner and Rector's The Kidney 2-Vol Set; Lippincott Illustrated Reviews Pharmacology

Valsartan (ARB - Angiotensin II Receptor Blocker)

Mechanism: Selective competitive antagonist of AT₁ (angiotensin II type 1) receptors. Blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II, resulting in arteriolar dilation, reduced aldosterone release (natriuresis), and decreased preload/afterload.

Key indications beyond hypertension:

Heart failure (reduces mortality/morbidity)
Post-MI with LV dysfunction (VALIANT trial: non-inferior to captopril for all-cause mortality)
Available as sacubitril/valsartan (Entresto) for HFrEF

Dosing: 80-320 mg once daily for hypertension

- Goodman & Gilman's Pharmacological Basis of Therapeutics

Rationale for the Combination

The combination is pharmacologically rational for several reasons:

Rationale	Explanation
Complementary mechanisms	CCB dilates via calcium blockade; ARB dilates via RAAS blockade - different pathways with additive BP reduction
Edema attenuation	Combining an ARB/ACEi with a CCB reduces CCB-associated peripheral edema by up to 38% (ARBs counteract CCB-induced precapillary dilation by also dilating postcapillary venules, reducing transcapillary pressure gradient)
Countering reflex activation	CCBs can trigger reflex renin/Ang II release; ARBs block this compensatory rise
Reduced BP variability	CCBs are among the most effective agents for reducing visit-to-visit BP variability, a predictor of stroke and MI
RAAS blockade	Protects kidneys and heart independently of BP lowering

- Brenner and Rector's The Kidney; Comprehensive Clinical Nephrology 7th Ed

Indications

Hypertension not controlled by monotherapy - the primary indication (Exforge)
Stage 2 hypertension - combination may be used as initial therapy when BP is >20/10 mmHg above target
Hypertension with CKD or diabetes - ARB component provides additional renoprotection
Hypertension with LV hypertrophy - ARB component reduces LVH
Hypertension + stable angina - amlodipine also reduces anginal episodes

Available Formulations (Exforge)

Amlodipine	Valsartan
5 mg	160 mg
10 mg	160 mg
5 mg	320 mg
10 mg	320 mg

A triple combination with HCTZ (Exforge HCT: amlodipine/valsartan/hydrochlorothiazide) is available for resistant hypertension, with trials showing superior BP control vs. dual therapy.

Adverse Effects

Drug	Key Adverse Effects
Amlodipine	Peripheral edema (dose-dependent), headache, flushing, palpitations, reflex tachycardia
Valsartan	Hyperkalemia (especially with CKD), hypotension (first dose), dizziness; rarely angioedema, hepatitis, neutropenia
Combination	Edema reduced vs. amlodipine alone; hypotension risk; avoid in bilateral renal artery stenosis

Contraindications / Precautions

Pregnancy - valsartan is teratogenic (Category D/X); discontinue immediately if pregnancy occurs
Bilateral renal artery stenosis - ARB can precipitate acute renal failure
Hyperkalemia - ARB caution with K+-sparing diuretics, K+ supplements, or renal disease
Severe aortic stenosis - CCB-mediated vasodilation may cause hemodynamic compromise
Do NOT combine with ACEi or aliskiren - dual RAAS blockade increases adverse renal outcomes without added CV benefit

Clinical Evidence

The VALUE trial compared valsartan- vs. amlodipine-based regimens in high-CV-risk hypertensive patients: amlodipine achieved faster initial BP control, but long-term CV outcomes were similar. The combination capitalizes on both drugs' strengths.

A 2023 network meta-analysis (PMID 37432701) confirmed that single-pill combinations including amlodipine/ARB were among the most effective regimens for BP control in uncontrolled hypertension.

The 2025 AHA/ACC Guideline lists CCB + ARB (or CCB + ACEi) as a preferred combination for most hypertensive patients, particularly those with diabetes, CKD, or high cardiovascular risk.

Create a dosing & monitoring protocol document for amlodipine/valsartan therapy

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Running Command

ls /home/daytona/workspace/ 2>/dev/null && ls /home/daytona/skills/docx/

Running Command

mkdir -p /home/daytona/workspace/amlodipine-valsartan-protocol

Writing File

~/amlodipine-valsartan-protocol/build.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageNumber, Header, Footer, TableOfContents,
  UnderlineType, PageBreak
} = require('docx');
const fs = require('fs');

// ── colour palette ──────────────────────────────────────────────────────────
const NAVY   = "1F3864";
const TEAL   = "1B6CA8";
const LBLUE  = "D6E4F0";
const LGREY  = "F2F2F2";
const WHITE  = "FFFFFF";
const RED    = "C0392B";
const ORANGE = "D68910";
const GREEN  = "1E8449";

// ── helpers ─────────────────────────────────────────────────────────────────
const bold  = (txt, size=20, color="000000") =>
  new TextRun({ text: txt, bold: true, size, color, font: "Calibri" });
const reg   = (txt, size=20, color="000000") =>
  new TextRun({ text: txt, size, color, font: "Calibri" });
const italic= (txt, size=20, color="000000") =>
  new TextRun({ text: txt, italics: true, size, color, font: "Calibri" });

const para = (children, opts={}) =>
  new Paragraph({ children: Array.isArray(children) ? children : [children], ...opts });

const hPara = (text, level) =>
  new Paragraph({
    text, heading: level,
    spacing: { before: 240, after: 120 },
  });

const bullet = (text, indent=0) =>
  new Paragraph({
    children: [reg(text, 19)],
    bullet: { level: indent },
    spacing: { before: 40, after: 40 },
  });

const note = (text) =>
  new Paragraph({
    children: [italic("Note: ", 18, "555555"), reg(text, 18, "555555")],
    spacing: { before: 60, after: 60 },
    indent: { left: 360 },
  });

// shaded cell
const shCell = (children, shColor=LBLUE, span=1, bold_=false) =>
  new TableCell({
    children: Array.isArray(children) ? children : [para(children)],
    shading: { type: ShadingType.CLEAR, color: "auto", fill: shColor },
    columnSpan: span,
    verticalAlign: VerticalAlign.CENTER,
    margins: { top: 80, bottom: 80, left: 120, right: 120 },
  });

const plainCell = (children, shColor=WHITE) =>
  new TableCell({
    children: Array.isArray(children) ? children : [para(children)],
    shading: { type: ShadingType.CLEAR, color: "auto", fill: shColor },
    verticalAlign: VerticalAlign.CENTER,
    margins: { top: 80, bottom: 80, left: 120, right: 120 },
  });

const hRow = (cells) => new TableRow({ children: cells, tableHeader: true });
const row  = (cells) => new TableRow({ children: cells });

// standard table with borders
const makeTable = (rows, widths) => new Table({
  rows,
  width: { size: 9500, type: WidthType.DXA },
  columnWidths: widths,
  borders: {
    top:    { style: BorderStyle.SINGLE, size: 6, color: TEAL },
    bottom: { style: BorderStyle.SINGLE, size: 6, color: TEAL },
    left:   { style: BorderStyle.SINGLE, size: 6, color: TEAL },
    right:  { style: BorderStyle.SINGLE, size: 6, color: TEAL },
    insideH:{ style: BorderStyle.SINGLE, size: 4, color: "CCCCCC" },
    insideV:{ style: BorderStyle.SINGLE, size: 4, color: "CCCCCC" },
  },
});

const spacer = (pt=120) => new Paragraph({ text: "", spacing: { before: pt, after: 0 } });

// ── cover page ───────────────────────────────────────────────────────────────
const coverPage = [
  spacer(1440),
  para([bold("CLINICAL DOSING & MONITORING PROTOCOL", 44, NAVY)],
    { alignment: AlignmentType.CENTER, spacing: { before: 0, after: 200 } }),
  para([bold("Amlodipine / Valsartan Combination Therapy", 36, TEAL)],
    { alignment: AlignmentType.CENTER, spacing: { before: 0, after: 200 } }),
  para([reg("(Exforge®  |  CCB + ARB Fixed-Dose Combination)", 24, "555555")],
    { alignment: AlignmentType.CENTER, spacing: { before: 0, after: 600 } }),

  // horizontal rule via border
  new Paragraph({
    children: [],
    border: { bottom: { style: BorderStyle.THICK, size: 12, color: TEAL } },
    spacing: { before: 0, after: 400 },
  }),

  para([bold("Document type:  ", 22, "333333"), reg("Clinical Protocol", 22)],
    { alignment: AlignmentType.CENTER, spacing: { before: 100, after: 80 } }),
  para([bold("Intended for:  ", 22, "333333"), reg("Physicians, Nurses, Clinical Pharmacists", 22)],
    { alignment: AlignmentType.CENTER, spacing: { before: 0, after: 80 } }),
  para([bold("Version:  ", 22, "333333"), reg("1.0", 22)],
    { alignment: AlignmentType.CENTER, spacing: { before: 0, after: 80 } }),
  para([bold("Date:  ", 22, "333333"), reg("May 2026", 22)],
    { alignment: AlignmentType.CENTER, spacing: { before: 0, after: 80 } }),
  para([bold("Based on:  ", 22, "333333"),
        reg("2025 AHA/ACC Hypertension Guideline; Goodman & Gilman's Pharmacological Basis of Therapeutics; Harrison's Principles of Internal Medicine 22E; Brenner & Rector's The Kidney; Comprehensive Clinical Nephrology 7th Ed", 22)],
    { alignment: AlignmentType.CENTER, spacing: { before: 0, after: 600 } }),

  new Paragraph({ children: [new PageBreak()] }),
];

// ── Section 1 – Drug Overview ────────────────────────────────────────────────
const sec1 = [
  hPara("1. Drug Overview", HeadingLevel.HEADING_1),
  hPara("1.1 Mechanism of Action", HeadingLevel.HEADING_2),

  makeTable([
    hRow([
      shCell([para([bold("Component", 20, WHITE)])], TEAL),
      shCell([para([bold("Class", 20, WHITE)])], TEAL),
      shCell([para([bold("Mechanism", 20, WHITE)])], TEAL),
    ]),
    row([
      plainCell([para([bold("Amlodipine", 20)])]),
      plainCell([para([reg("Dihydropyridine Calcium Channel Blocker (CCB)", 20)])]),
      plainCell([para([reg("Blocks L-type voltage-gated Ca²⁺ channels in vascular smooth muscle → peripheral arteriolar vasodilation → reduced systemic vascular resistance and afterload. Binds dihydropyridine and non-dihydropyridine receptor sites; no significant AV nodal or negative inotropic effect.", 20)])]),
    ]),
    row([
      plainCell([para([bold("Valsartan", 20)])], LGREY),
      plainCell([para([reg("Angiotensin II Receptor Blocker (ARB)", 20)])], LGREY),
      plainCell([para([reg("Selective competitive antagonist of AT₁ receptors → blocks vasoconstriction and aldosterone release mediated by angiotensin II → arteriolar and venous dilation, natriuresis, reduction of preload and afterload.", 20)])], LGREY),
    ]),
  ], [1700, 2300, 5500]),

  spacer(160),
  hPara("1.2 Pharmacokinetics at a Glance", HeadingLevel.HEADING_2),

  makeTable([
    hRow([
      shCell([para([bold("Parameter", 20, WHITE)])], TEAL),
      shCell([para([bold("Amlodipine", 20, WHITE)])], TEAL),
      shCell([para([bold("Valsartan", 20, WHITE)])], TEAL),
    ]),
    row([
      plainCell([para([bold("Bioavailability", 20)])]),
      plainCell([para([reg("~60–65%", 20)])]),
      plainCell([para([reg("~25% (low, but consistent)", 20)])]),
    ]),
    row([
      plainCell([para([bold("T½ (half-life)", 20)])], LGREY),
      plainCell([para([bold("30–50 h", 20, RED)])], LGREY),
      plainCell([para([reg("6–9 h", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Time to peak", 20)])]),
      plainCell([para([reg("6–12 h (steady-state in 7–8 days)", 20)])]),
      plainCell([para([reg("2–4 h", 20)])]),
    ]),
    row([
      plainCell([para([bold("Protein binding", 20)])], LGREY),
      plainCell([para([reg(">97%", 20)])], LGREY),
      plainCell([para([reg(">94%", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Metabolism", 20)])]),
      plainCell([para([reg("Hepatic (~90%)", 20)])]),
      plainCell([para([reg("Hepatic (CYP2C9 minor)", 20)])]),
    ]),
    row([
      plainCell([para([bold("Excretion", 20)])], LGREY),
      plainCell([para([reg("Urine (metabolites) + feces", 20)])], LGREY),
      plainCell([para([reg("Feces (~83%), Urine (~13%)", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Renal dose adjustment", 20)])]),
      plainCell([para([reg("Not required", 20, GREEN)])]),
      plainCell([para([reg("Not required (mild–moderate CKD)", 20, GREEN)])]),
    ]),
    row([
      plainCell([para([bold("Hepatic dose adjustment", 20)])], LGREY),
      plainCell([para([bold("Required (start 2.5 mg)", 20, ORANGE)])], LGREY),
      plainCell([para([bold("Required (max 80 mg/day)", 20, ORANGE)])], LGREY),
    ]),
  ], [2500, 3500, 3500]),

  spacer(160),
  hPara("1.3 Rationale for Combination", HeadingLevel.HEADING_2),
  bullet("Complementary mechanisms: CCB acts on Ca²⁺ channels; ARB acts on RAAS — additive BP reduction"),
  bullet("ARB blunts reflex renin/Ang II activation triggered by CCB-induced vasodilation"),
  bullet("ARB co-administration reduces CCB-associated peripheral edema by up to 38% (by dilating postcapillary venules, reducing transcapillary pressure gradient)"),
  bullet("Reduced BP visit-to-visit variability compared with monotherapy — important for stroke/MI risk reduction"),
  bullet("Organ protection: ARB provides independent nephro- and cardioprotection beyond BP lowering"),
  bullet("Single-pill formulation (Exforge®) improves adherence and treatment persistence"),
  spacer(),
];

// ── Section 2 – Indications & Contraindications ──────────────────────────────
const sec2 = [
  hPara("2. Indications & Contraindications", HeadingLevel.HEADING_1),
  hPara("2.1 Approved Indications", HeadingLevel.HEADING_2),
  bullet("Hypertension not adequately controlled by amlodipine monotherapy or valsartan monotherapy"),
  bullet("Stage 2 hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg) as initial combination therapy when BP is >20/10 mmHg above target"),
  bullet("Hypertension with comorbid type 2 diabetes mellitus — ARB provides renoprotection"),
  bullet("Hypertension with CKD (eGFR ≥15 mL/min/1.73 m²) — ARB slows proteinuria progression"),
  bullet("Hypertension with stable angina pectoris — amlodipine component reduces anginal episodes"),
  bullet("Hypertension with left ventricular hypertrophy — ARB promotes LVH regression"),
  spacer(80),

  hPara("2.2 Contraindications", HeadingLevel.HEADING_2),

  makeTable([
    hRow([
      shCell([para([bold("Contraindication", 20, WHITE)])], RED),
      shCell([para([bold("Applies to", 20, WHITE)])], RED),
      shCell([para([bold("Reason", 20, WHITE)])], RED),
    ]),
    row([
      plainCell([para([bold("Pregnancy (any trimester)", 20)])]),
      plainCell([para([reg("Valsartan", 20)])]),
      plainCell([para([reg("Fetotoxic; causes oligohydramnios, renal failure, death. ACOG Category D/X. Discontinue immediately if pregnancy confirmed.", 20)])]),
    ]),
    row([
      plainCell([para([bold("Bilateral renal artery stenosis", 20)])], LGREY),
      plainCell([para([reg("Valsartan", 20)])], LGREY),
      plainCell([para([reg("Loss of AT₁-mediated efferent tone → acute renal failure", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Concomitant ACEi + ARB dual RAAS blockade", 20)])]),
      plainCell([para([reg("Valsartan", 20)])]),
      plainCell([para([reg("ONTARGET trial: no CV benefit; increased hypotension, hyperkalemia, renal failure", 20)])]),
    ]),
    row([
      plainCell([para([bold("Concomitant aliskiren in diabetes/CKD", 20)])], LGREY),
      plainCell([para([reg("Valsartan", 20)])], LGREY),
      plainCell([para([reg("Increased adverse renal outcomes", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Hypersensitivity to amlodipine or valsartan", 20)])]),
      plainCell([para([reg("Both", 20)])]),
      plainCell([para([reg("Standard allergy contraindication", 20)])]),
    ]),
    row([
      plainCell([para([bold("Severe aortic stenosis", 20)])], LGREY),
      plainCell([para([reg("Amlodipine (relative)", 20)])], LGREY),
      plainCell([para([reg("Fixed outflow obstruction; vasodilation may precipitate hemodynamic collapse", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Severe hepatic impairment (Child-Pugh C)", 20)])]),
      plainCell([para([reg("Both", 20)])]),
      plainCell([para([reg("Markedly impaired drug clearance; avoid or use with extreme caution", 20)])]),
    ]),
  ], [2800, 1700, 5000]),
  spacer(),
];

// ── Section 3 – Dosing Protocol ──────────────────────────────────────────────
const sec3 = [
  hPara("3. Dosing Protocol", HeadingLevel.HEADING_1),
  hPara("3.1 Available Formulations (Exforge®)", HeadingLevel.HEADING_2),

  makeTable([
    hRow([
      shCell([para([bold("Tablet Strength", 20, WHITE)])], NAVY),
      shCell([para([bold("Amlodipine", 20, WHITE)])], NAVY),
      shCell([para([bold("Valsartan", 20, WHITE)])], NAVY),
      shCell([para([bold("Clinical Use", 20, WHITE)])], NAVY),
    ]),
    row([
      plainCell([para([reg("Exforge® 5/160", 20)])]),
      plainCell([para([reg("5 mg", 20)])]),
      plainCell([para([reg("160 mg", 20)])]),
      plainCell([para([reg("Standard starting dose; BP 20–30 mmHg above target", 20)])]),
    ]),
    row([
      plainCell([para([reg("Exforge® 10/160", 20)])], LGREY),
      plainCell([para([reg("10 mg", 20)])], LGREY),
      plainCell([para([reg("160 mg", 20)])], LGREY),
      plainCell([para([reg("Titration step when higher CCB dose needed", 20)])], LGREY),
    ]),
    row([
      plainCell([para([reg("Exforge® 5/320", 20)])]),
      plainCell([para([reg("5 mg", 20)])]),
      plainCell([para([reg("320 mg", 20)])]),
      plainCell([para([reg("Titration step when higher ARB dose needed", 20)])]),
    ]),
    row([
      plainCell([para([reg("Exforge® 10/320", 20)])], LGREY),
      plainCell([para([reg("10 mg", 20)])], LGREY),
      plainCell([para([reg("320 mg", 20)])], LGREY),
      plainCell([para([bold("Maximum dose; resistant hypertension", 20)])], LGREY),
    ]),
  ], [2000, 1800, 1800, 3900]),

  spacer(160),
  hPara("3.2 Standard Dosing — General Adult", HeadingLevel.HEADING_2),

  makeTable([
    hRow([
      shCell([para([bold("Step", 20, WHITE)])], TEAL),
      shCell([para([bold("Action", 20, WHITE)])], TEAL),
      shCell([para([bold("Dose", 20, WHITE)])], TEAL),
      shCell([para([bold("Timing", 20, WHITE)])], TEAL),
    ]),
    row([
      plainCell([para([bold("Initiation", 20)])]),
      plainCell([para([reg("Start combination therapy (switching from monotherapy or initiating for Stage 2 HTN)", 20)])]),
      plainCell([para([bold("Amlodipine 5 mg / Valsartan 160 mg once daily", 20, TEAL)])]),
      plainCell([para([reg("Once daily at same time each day; may be taken with or without food", 20)])]),
    ]),
    row([
      plainCell([para([bold("Titration", 20)])], LGREY),
      plainCell([para([reg("If target BP not achieved after 1–2 weeks, uptitrate", 20)])], LGREY),
      plainCell([para([reg("Increase to 10/160 mg OR 5/320 mg", 20)])], LGREY),
      plainCell([para([reg("Allow 1–2 weeks between dose increases", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Maximum", 20)])]),
      plainCell([para([reg("For persistent uncontrolled hypertension", 20)])]),
      plainCell([para([bold("Amlodipine 10 mg / Valsartan 320 mg once daily", 20, RED)])]),
      plainCell([para([reg("Once daily; reassess need to add 3rd agent (e.g. HCTZ) if still uncontrolled", 20)])]),
    ]),
  ], [1500, 3000, 2500, 2500]),

  note("Antihypertensive effect is detectable within 24 h; maximal effect may take 2–4 weeks due to amlodipine's long half-life (30–50 h) and required steady-state accumulation (7–8 days)."),
  spacer(160),

  hPara("3.3 Dose Adjustments — Special Populations", HeadingLevel.HEADING_2),

  makeTable([
    hRow([
      shCell([para([bold("Population", 20, WHITE)])], NAVY),
      shCell([para([bold("Amlodipine Adjustment", 20, WHITE)])], NAVY),
      shCell([para([bold("Valsartan Adjustment", 20, WHITE)])], NAVY),
      shCell([para([bold("Notes", 20, WHITE)])], NAVY),
    ]),
    row([
      plainCell([para([bold("Elderly (≥65 years)", 20)])]),
      plainCell([para([bold("Start 2.5 mg", 20, ORANGE)])]),
      plainCell([para([reg("Standard dosing; monitor BP closely for first-dose hypotension", 20)])]),
      plainCell([para([reg("Prolonged half-life in elderly; slower titration recommended", 20)])]),
    ]),
    row([
      plainCell([para([bold("Mild–Moderate CKD (eGFR 15–59)", 20)])], LGREY),
      plainCell([para([reg("No adjustment", 20, GREEN)])], LGREY),
      plainCell([para([reg("No adjustment (use with caution if eGFR <30)", 20, GREEN)])], LGREY),
      plainCell([para([reg("Monitor eGFR, potassium, creatinine closely every 1–3 months", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Severe CKD (eGFR <15) / Dialysis", 20)])]),
      plainCell([para([reg("No adjustment", 20, GREEN)])]),
      plainCell([para([bold("Use with caution; limited data", 20, ORANGE)])]),
      plainCell([para([reg("Risk of hyperkalemia and hypotension significantly increased", 20)])]),
    ]),
    row([
      plainCell([para([bold("Mild Hepatic Impairment (Child-Pugh A)", 20)])], LGREY),
      plainCell([para([bold("Start 2.5 mg; titrate slowly", 20, ORANGE)])], LGREY),
      plainCell([para([bold("Max 80 mg/day", 20, ORANGE)])], LGREY),
      plainCell([para([reg("Impaired clearance of both drugs; monitor LFTs", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Moderate Hepatic Impairment (Child-Pugh B)", 20)])]),
      plainCell([para([bold("Start 2.5 mg; titrate slowly", 20, ORANGE)])]),
      plainCell([para([bold("Use with caution; max 80 mg/day", 20, ORANGE)])]),
      plainCell([para([reg("Significant PK alteration; close monitoring required", 20)])]),
    ]),
    row([
      plainCell([para([bold("Severe Hepatic Impairment (Child-Pugh C)", 20)])], LGREY),
      plainCell([para([bold("AVOID or use with extreme caution", 20, RED)])], LGREY),
      plainCell([para([bold("CONTRAINDICATED", 20, RED)])], LGREY),
      plainCell([para([reg("Consider alternative antihypertensive regimen", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Pregnancy", 20)])]),
      plainCell([para([bold("Use only if clearly needed (Category C T1; D T2–3)", 20, ORANGE)])]),
      plainCell([para([bold("CONTRAINDICATED (all trimesters)", 20, RED)])]),
      plainCell([para([reg("Discontinue entire combination immediately upon confirmed pregnancy; switch to methyldopa or labetalol", 20)])]),
    ]),
    row([
      plainCell([para([bold("Breastfeeding", 20)])], LGREY),
      plainCell([para([bold("Not recommended", 20, ORANGE)])], LGREY),
      plainCell([para([bold("Not recommended", 20, ORANGE)])], LGREY),
      plainCell([para([reg("Both drugs may pass into breast milk; consider alternative therapy", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Paediatric (<18 years)", 20)])]),
      plainCell([para([reg("Not established", 20, ORANGE)])]),
      plainCell([para([reg("Not established", 20, ORANGE)])]),
      plainCell([para([reg("Fixed combination not approved in children; dose individual components if needed", 20)])]),
    ]),
  ], [2000, 2000, 2000, 3500]),
  spacer(),
];

// ── Section 4 – BP Targets ────────────────────────────────────────────────────
const sec4 = [
  hPara("4. Blood Pressure Targets", HeadingLevel.HEADING_1),

  makeTable([
    hRow([
      shCell([para([bold("Patient Population", 20, WHITE)])], TEAL),
      shCell([para([bold("Target BP (2025 AHA/ACC)", 20, WHITE)])], TEAL),
      shCell([para([bold("Target BP (2024 ESC)", 20, WHITE)])], TEAL),
    ]),
    row([
      plainCell([para([bold("General adults (low–moderate risk)", 20)])]),
      plainCell([para([bold("<130/80 mmHg", 20, TEAL)])]),
      plainCell([para([bold("<140/90 mmHg (or <130/80 if tolerated)", 20, TEAL)])]),
    ]),
    row([
      plainCell([para([bold("Diabetes mellitus", 20)])], LGREY),
      plainCell([para([bold("<130/80 mmHg", 20, TEAL)])], LGREY),
      plainCell([para([bold("<130/80 mmHg", 20, TEAL)])], LGREY),
    ]),
    row([
      plainCell([para([bold("CKD (with or without proteinuria)", 20)])]),
      plainCell([para([bold("<130/80 mmHg", 20, TEAL)])]),
      plainCell([para([bold("<130/80 mmHg", 20, TEAL)])]),
    ]),
    row([
      plainCell([para([bold("CAD / High ASCVD risk (10-yr risk ≥10%)", 20)])], LGREY),
      plainCell([para([bold("<130/80 mmHg", 20, TEAL)])], LGREY),
      plainCell([para([bold("<130/80 mmHg", 20, TEAL)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Heart failure", 20)])]),
      plainCell([para([bold("<130/80 mmHg", 20, TEAL)])]),
      plainCell([para([bold("<130/80 mmHg", 20, TEAL)])]),
    ]),
    row([
      plainCell([para([bold("Elderly ≥65 years (isolated systolic HTN)", 20)])], LGREY),
      plainCell([para([bold("SBP 130–139 mmHg", 20, TEAL)])], LGREY),
      plainCell([para([bold("SBP 140–150 mmHg (or <140 if tolerated)", 20, TEAL)])], LGREY),
    ]),
  ], [3200, 3150, 3150]),

  spacer(80),
  note("When SBP and DBP targets conflict, use the more stringent target. Reassess risk/benefit in frail elderly patients — avoid over-treatment."),
  spacer(),
];

// ── Section 5 – Monitoring Protocol ──────────────────────────────────────────
const sec5 = [
  hPara("5. Monitoring Protocol", HeadingLevel.HEADING_1),
  hPara("5.1 Baseline Assessment (Before Initiation)", HeadingLevel.HEADING_2),

  makeTable([
    hRow([
      shCell([para([bold("Parameter", 20, WHITE)])], NAVY),
      shCell([para([bold("Action / Rationale", 20, WHITE)])], NAVY),
    ]),
    row([
      plainCell([para([bold("Blood pressure", 20)])]),
      plainCell([para([reg("Measure ≥2 readings on ≥2 separate occasions; use validated oscillometric device; arm with higher reading. Confirm with ABPM or HBPM if white-coat hypertension suspected.", 20)])]),
    ]),
    row([
      plainCell([para([bold("Renal function", 20)])], LGREY),
      plainCell([para([reg("Serum creatinine, eGFR, BUN — ARB may reduce efferent arteriolar tone; an eGFR rise of ≤30% from baseline is acceptable; >30% warrants ARB dose reduction or discontinuation", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Serum potassium", 20)])]),
      plainCell([para([reg("Valsartan blocks aldosterone release → potassium retention. Check baseline K⁺; target 3.5–5.0 mEq/L. Hyperkalemia risk increased with CKD, DM, concurrent K⁺-sparing diuretics.", 20)])]),
    ]),
    row([
      plainCell([para([bold("Liver function tests (LFTs)", 20)])], LGREY),
      plainCell([para([reg("Both drugs hepatically metabolized; dose adjustment needed for hepatic impairment. Check ALT, AST, bilirubin, albumin, INR.", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Serum sodium", 20)])]),
      plainCell([para([reg("Valsartan may rarely cause hyponatremia; baseline value guides monitoring.", 20)])]),
    ]),
    row([
      plainCell([para([bold("Pregnancy test (women of childbearing age)", 20)])], LGREY),
      plainCell([para([reg("Valsartan is teratogenic. Confirm negative before prescribing. Discuss contraception.", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Medication review", 20)])]),
      plainCell([para([reg("Check for concomitant ACEi, aliskiren, K⁺ supplements, NSAIDs, potassium-sparing diuretics, CYP3A4 inhibitors (e.g. clarithromycin, ketoconazole — increase amlodipine exposure)", 20)])]),
    ]),
    row([
      plainCell([para([bold("Cardiovascular history", 20)])], LGREY),
      plainCell([para([reg("Document prior MI, HF (EF), LVH, aortic stenosis, stroke — influences BP target and suitability of CCB", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Bilateral renal artery stenosis screening", 20)])]),
      plainCell([para([reg("Ask about history; suspect if rapid onset hypertension in young patient or difficult-to-control HTN in atherosclerotic patient; duplex ultrasound if suspected", 20)])]),
    ]),
  ], [2800, 6700]),

  spacer(160),
  hPara("5.2 Follow-up Monitoring Schedule", HeadingLevel.HEADING_2),

  makeTable([
    hRow([
      shCell([para([bold("Timepoint", 20, WHITE)])], TEAL),
      shCell([para([bold("BP Check", 20, WHITE)])], TEAL),
      shCell([para([bold("Labs", 20, WHITE)])], TEAL),
      shCell([para([bold("Clinical Assessment", 20, WHITE)])], TEAL),
    ]),
    row([
      plainCell([para([bold("1–2 weeks post-initiation", 20)])]),
      plainCell([para([reg("Office BP; home diary if available", 20)])]),
      plainCell([para([reg("Serum K⁺, creatinine, eGFR", 20)])]),
      plainCell([para([reg("Symptoms of hypotension (dizziness, syncope); edema assessment; medication tolerance", 20)])]),
    ]),
    row([
      plainCell([para([bold("4–6 weeks (after any dose change)", 20)])], LGREY),
      plainCell([para([reg("Office BP; consider ABPM if inadequate control", 20)])], LGREY),
      plainCell([para([reg("K⁺, creatinine — especially after ARB dose increase", 20)])], LGREY),
      plainCell([para([reg("Assess BP target achievement; review adherence; adverse effects", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("3 months", 20)])]),
      plainCell([para([reg("Office BP; HBPM readings if available", 20)])]),
      plainCell([para([reg("K⁺, creatinine, eGFR, Na⁺; LFTs if hepatic impairment", 20)])]),
      plainCell([para([reg("Dose optimization if BP not at target; assess edema; check for masked/white-coat HTN", 20)])]),
    ]),
    row([
      plainCell([para([bold("Every 6 months (stable patients)", 20)])], LGREY),
      plainCell([para([reg("Office BP ± HBPM review", 20)])], LGREY),
      plainCell([para([reg("K⁺, creatinine, eGFR; annual LFTs", 20)])], LGREY),
      plainCell([para([reg("Cardiovascular risk review; medication adherence; lifestyle factors; annual ECG if LVH", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Annual", 20)])]),
      plainCell([para([reg("Full BP profile; consider 24-h ABPM", 20)])]),
      plainCell([para([reg("Full metabolic panel: K⁺, Na⁺, creatinine, eGFR, glucose, HbA1c (if DM), LFTs, lipids", 20)])]),
      plainCell([para([reg("Reassess CV risk; check for new contraindications; review pregnancy status if applicable", 20)])]),
    ]),
    row([
      plainCell([para([bold("Any dose escalation", 20)])], LGREY),
      plainCell([para([reg("BP check at 1–2 weeks post-change", 20)])], LGREY),
      plainCell([para([reg("K⁺, creatinine within 2 weeks", 20)])], LGREY),
      plainCell([para([reg("Hypotension symptoms, edema, renal function", 20)])], LGREY),
    ]),
  ], [2000, 2000, 2500, 3000]),

  spacer(160),
  hPara("5.3 Critical Lab Thresholds — Action Required", HeadingLevel.HEADING_2),

  makeTable([
    hRow([
      shCell([para([bold("Parameter", 20, WHITE)])], RED),
      shCell([para([bold("Threshold", 20, WHITE)])], RED),
      shCell([para([bold("Action", 20, WHITE)])], RED),
    ]),
    row([
      plainCell([para([bold("Serum K⁺", 20)])]),
      plainCell([para([bold(">5.5 mEq/L", 20, RED)])]),
      plainCell([para([reg("Reduce or suspend valsartan; review concurrent medications; dietary counselling; repeat K⁺ in 1 week", 20)])]),
    ]),
    row([
      plainCell([para([bold("Serum K⁺", 20)])], LGREY),
      plainCell([para([bold(">6.0 mEq/L", 20, RED)])], LGREY),
      plainCell([para([bold("Discontinue valsartan; urgent review; ECG", 20, RED)])], LGREY),
    ]),
    row([
      plainCell([para([bold("eGFR decline", 20)])]),
      plainCell([para([bold(">30% from baseline", 20, RED)])]),
      plainCell([para([reg("Withhold valsartan; investigate for volume depletion, renovascular disease; nephrology consult", 20)])]),
    ]),
    row([
      plainCell([para([bold("eGFR decline", 20)])], LGREY),
      plainCell([para([bold("≤30% from baseline", 20, ORANGE)])], LGREY),
      plainCell([para([reg("Acceptable; monitor more frequently (every 4 weeks); optimize volume status", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Serum creatinine", 20)])]),
      plainCell([para([bold("Rise >50% from baseline", 20, RED)])]),
      plainCell([para([reg("Withhold valsartan; investigate for renal artery stenosis, hypovolaemia; seek specialist input", 20)])]),
    ]),
    row([
      plainCell([para([bold("ALT/AST", 20)])], LGREY),
      plainCell([para([bold(">3× ULN", 20, ORANGE)])], LGREY),
      plainCell([para([reg("Reduce dose; reassess. If >5× ULN or symptomatic hepatitis: discontinue both drugs; hepatology consult", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("SBP (hypotension)", 20)])]),
      plainCell([para([bold("<90 mmHg symptomatic", 20, RED)])]),
      plainCell([para([reg("Hold combination; assess volume status; reduce dose; review all antihypertensives and diuretics", 20)])]),
    ]),
  ], [2000, 2500, 5000]),
  spacer(),
];

// ── Section 6 – Adverse Effects ───────────────────────────────────────────────
const sec6 = [
  hPara("6. Adverse Effects & Management", HeadingLevel.HEADING_1),

  makeTable([
    hRow([
      shCell([para([bold("Adverse Effect", 20, WHITE)])], NAVY),
      shCell([para([bold("Drug", 20, WHITE)])], NAVY),
      shCell([para([bold("Frequency", 20, WHITE)])], NAVY),
      shCell([para([bold("Management", 20, WHITE)])], NAVY),
    ]),
    row([
      plainCell([para([bold("Peripheral edema", 20)])]),
      plainCell([para([reg("Amlodipine (dose-dependent)", 20)])]),
      plainCell([para([reg("Up to 10–15% at 10 mg", 20)])]),
      plainCell([para([reg("ARB co-administration reduces incidence by ~38%. If persistent: reduce amlodipine dose; consider switching CCB to lercanidipine (less edema).", 20)])]),
    ]),
    row([
      plainCell([para([bold("Flushing / headache", 20)])], LGREY),
      plainCell([para([reg("Amlodipine", 20)])], LGREY),
      plainCell([para([reg("Common at initiation", 20)])], LGREY),
      plainCell([para([reg("Usually transient; typically resolves within 2–4 weeks. Reassure patient.", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Palpitations / reflex tachycardia", 20)])]),
      plainCell([para([reg("Amlodipine", 20)])]),
      plainCell([para([reg("Uncommon", 20)])]),
      plainCell([para([reg("Usually mild; if severe or sustained: ECG; consider adding low-dose beta-blocker if clinically appropriate.", 20)])]),
    ]),
    row([
      plainCell([para([bold("Hypotension (esp. first-dose)", 20)])], LGREY),
      plainCell([para([reg("Valsartan (+ amlodipine additive)", 20)])], LGREY),
      plainCell([para([reg("Uncommon; higher risk if volume-depleted", 20)])], LGREY),
      plainCell([para([reg("Advise patient to rise slowly; avoid dehydration; take medication in evening if problematic. Reduce dose if symptomatic.", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Hyperkalemia", 20)])]),
      plainCell([para([reg("Valsartan", 20)])]),
      plainCell([para([reg("Risk increases with CKD, DM, K⁺-sparing diuretics", 20)])]),
      plainCell([para([reg("Monitor K⁺ regularly. Dietary K⁺ restriction if mild. Dose reduction or discontinue if K⁺ >5.5 mEq/L.", 20)])]),
    ]),
    row([
      plainCell([para([bold("Dizziness / light-headedness", 20)])], LGREY),
      plainCell([para([reg("Both", 20)])], LGREY),
      plainCell([para([reg("Common at initiation or dose increase", 20)])], LGREY),
      plainCell([para([reg("Reassess BP; check for orthostatic hypotension (standing and supine BP). Dose reduction if persistent.", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Renal function deterioration", 20)])]),
      plainCell([para([reg("Valsartan", 20)])]),
      plainCell([para([reg("Up to 30% eGFR decline acceptable", 20)])]),
      plainCell([para([reg("Acceptable rise in creatinine up to 30% from baseline. >30%: investigate and withhold. See Section 5.3.", 20)])]),
    ]),
    row([
      plainCell([para([bold("Angioedema", 20)])], LGREY),
      plainCell([para([reg("Valsartan (rare)", 20)])], LGREY),
      plainCell([para([reg("Very rare (<0.1%) — less than ACEi", 20)])], LGREY),
      plainCell([para([reg("Discontinue immediately; treat as anaphylaxis if severe; do NOT rechallenge with any ARB or ACEi if confirmed angioedema.", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Hepatotoxicity", 20)])]),
      plainCell([para([reg("Both (rare)", 20)])]),
      plainCell([para([reg("Rare; case reports post-marketing", 20)])]),
      plainCell([para([reg("Monitor LFTs annually (or more frequently in hepatic impairment). Discontinue if >5× ULN or symptomatic.", 20)])]),
    ]),
    row([
      plainCell([para([bold("Gingival hyperplasia", 20)])], LGREY),
      plainCell([para([reg("Amlodipine (CCB class effect)", 20)])], LGREY),
      plainCell([para([reg("Rare", 20)])], LGREY),
      plainCell([para([reg("Dental hygiene optimisation; consider switching CCB class if severe.", 20)])], LGREY),
    ]),
  ], [2300, 2200, 1800, 3200]),
  spacer(),
];

// ── Section 7 – Drug Interactions ─────────────────────────────────────────────
const sec7 = [
  hPara("7. Key Drug Interactions", HeadingLevel.HEADING_1),

  makeTable([
    hRow([
      shCell([para([bold("Interacting Drug / Class", 20, WHITE)])], NAVY),
      shCell([para([bold("Effect", 20, WHITE)])], NAVY),
      shCell([para([bold("Clinical Action", 20, WHITE)])], NAVY),
      shCell([para([bold("Severity", 20, WHITE)])], NAVY),
    ]),
    row([
      plainCell([para([bold("ACE inhibitors (e.g. lisinopril)", 20)])]),
      plainCell([para([reg("Dual RAAS blockade → additive hypotension, hyperkalemia, renal failure", 20)])]),
      plainCell([para([reg("AVOID combination", 20)])]),
      shCell([para([bold("CONTRAINDICATED", 20, WHITE)])], RED),
    ]),
    row([
      plainCell([para([bold("Aliskiren (in DM/CKD)", 20)])], LGREY),
      plainCell([para([reg("Triple RAAS blockade → severe hypotension, hyperkalemia, renal failure", 20)])], LGREY),
      plainCell([para([reg("AVOID", 20)])], LGREY),
      shCell([para([bold("CONTRAINDICATED", 20, WHITE)])], RED),
    ]),
    row([
      plainCell([para([bold("K⁺-sparing diuretics (spironolactone, amiloride)", 20)])]),
      plainCell([para([reg("Additive hyperkalemia risk with valsartan", 20)])]),
      plainCell([para([reg("Monitor K⁺ closely; consider dose reduction", 20)])]),
      shCell([para([bold("Major", 20, WHITE)])], ORANGE),
    ]),
    row([
      plainCell([para([bold("NSAIDs (e.g. ibuprofen, indomethacin)", 20)])], LGREY),
      plainCell([para([reg("Blunt antihypertensive effect; additive nephrotoxicity with ARB", 20)])], LGREY),
      plainCell([para([reg("Avoid regular NSAID use; use paracetamol (acetaminophen) instead", 20)])], LGREY),
      shCell([para([bold("Major", 20, WHITE)])], ORANGE),
    ]),
    row([
      plainCell([para([bold("Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir)", 20)])]),
      plainCell([para([reg("Inhibit amlodipine metabolism → increased amlodipine plasma levels → enhanced BP lowering and edema", 20)])]),
      plainCell([para([reg("Monitor BP closely; consider amlodipine dose reduction", 20)])]),
      shCell([para([bold("Moderate", 20, WHITE)])], ORANGE),
    ]),
    row([
      plainCell([para([bold("Strong CYP3A4 inducers (rifampicin, carbamazepine, St John's Wort)", 20)])], LGREY),
      plainCell([para([reg("Increase amlodipine metabolism → reduced BP-lowering efficacy", 20)])], LGREY),
      plainCell([para([reg("Monitor BP; consider dose adjustment or alternative antihypertensive", 20)])], LGREY),
      shCell([para([bold("Moderate", 20, WHITE)])], ORANGE),
    ]),
    row([
      plainCell([para([bold("Simvastatin (>20 mg/day)", 20)])]),
      plainCell([para([reg("Amlodipine inhibits CYP3A4 → increased simvastatin exposure → myopathy risk", 20)])]),
      plainCell([para([reg("Cap simvastatin at 20 mg/day with amlodipine; or switch to rosuvastatin/pravastatin", 20)])]),
      shCell([para([bold("Moderate", 20, WHITE)])], ORANGE),
    ]),
    row([
      plainCell([para([bold("Lithium", 20)])], LGREY),
      plainCell([para([reg("ARBs may increase lithium levels → lithium toxicity", 20)])], LGREY),
      plainCell([para([reg("Monitor lithium levels closely if concurrent use required", 20)])], LGREY),
      shCell([para([bold("Moderate", 20, WHITE)])], ORANGE),
    ]),
    row([
      plainCell([para([bold("Potassium supplements / salt substitutes", 20)])]),
      plainCell([para([reg("Additive hyperkalemia with ARB", 20)])]),
      plainCell([para([reg("Avoid unless serum K⁺ closely monitored", 20)])]),
      shCell([para([bold("Moderate", 20, WHITE)])], ORANGE),
    ]),
    row([
      plainCell([para([bold("Other antihypertensives", 20)])], LGREY),
      plainCell([para([reg("Additive BP-lowering effect", 20)])], LGREY),
      plainCell([para([reg("Titrate carefully; monitor for hypotension. Beneficial in resistant HTN if used intentionally.", 20)])], LGREY),
      shCell([para([bold("Minor–Moderate", 20, WHITE)])], LGREY),
    ]),
  ], [2300, 2500, 2500, 1700]),
  spacer(),
];

// ── Section 8 – Patient Counselling ──────────────────────────────────────────
const sec8 = [
  hPara("8. Patient Counselling Points", HeadingLevel.HEADING_1),
  hPara("Administration", HeadingLevel.HEADING_2),
  bullet("Take once daily at the same time each day — with or without food"),
  bullet("Do not crush or chew tablets; swallow whole"),
  bullet("If a dose is missed, take as soon as remembered the same day. If the next day, skip the missed dose — do not double up"),
  bullet("Antihypertensive effect builds gradually; maximal effect may take 2–4 weeks. Continue taking even if you feel well"),

  hPara("Lifestyle Modifications (Foundational Therapy)", HeadingLevel.HEADING_2),
  bullet("Sodium restriction: target <2 g/day (5 g salt/day) — enhances ARB efficacy"),
  bullet("Maintain healthy weight (BMI 18.5–24.9 kg/m²) — each 1 kg weight loss lowers SBP by ~1 mmHg"),
  bullet("Regular aerobic exercise: ≥150 minutes moderate-intensity per week"),
  bullet("Limit alcohol: ≤1 standard drink/day (women), ≤2/day (men)"),
  bullet("Stop smoking: smoking blunts antihypertensive drug efficacy"),
  bullet("DASH diet: rich in fruits, vegetables, whole grains, low-fat dairy; reduces SBP by 8–14 mmHg"),

  hPara("Safety Warnings", HeadingLevel.HEADING_2),
  bullet("Pregnancy: Inform your doctor IMMEDIATELY if you become pregnant. Valsartan is harmful to the unborn baby. Effective contraception is essential while taking this medication."),
  bullet("Avoid K⁺-rich salt substitutes (e.g. potassium chloride-based) without medical advice — risk of high potassium"),
  bullet("Inform all healthcare providers (dentists, surgeons) you are taking this medication before any procedure"),
  bullet("Avoid prolonged NSAID use (ibuprofen, naproxen) — may reduce blood pressure control and harm the kidneys"),
  bullet("Dizziness on standing (orthostatic hypotension): rise slowly from sitting or lying, especially in the first weeks of therapy"),
  bullet("Peripheral ankle swelling: mild edema may occur, particularly with amlodipine. Report if severe or new-onset facial/lip/tongue swelling (possible angioedema — seek emergency care)"),
  bullet("Home BP monitoring: Keep a logbook; bring readings to each clinic visit"),
  spacer(),
];

// ── Section 9 – When to Escalate / Refer ─────────────────────────────────────
const sec9 = [
  hPara("9. When to Escalate or Refer", HeadingLevel.HEADING_1),

  makeTable([
    hRow([
      shCell([para([bold("Clinical Situation", 20, WHITE)])], NAVY),
      shCell([para([bold("Action", 20, WHITE)])], NAVY),
    ]),
    row([
      plainCell([para([bold("BP remains >160/100 mmHg on maximum dose", 20)])]),
      plainCell([para([reg("Add 3rd agent (e.g. hydrochlorothiazide 12.5–25 mg or Exforge HCT); refer to hypertension specialist for resistant HTN workup", 20)])]),
    ]),
    row([
      plainCell([para([bold("BP remains uncontrolled on ≥3 agents including a diuretic", 20)])], LGREY),
      plainCell([para([bold("Refer to hypertension specialist — consider secondary causes (primary aldosteronism, renal artery stenosis, Cushing's, phaeochromocytoma)", 20, RED)])], LGREY),
    ]),
    row([
      plainCell([para([bold("K⁺ >6.0 mEq/L or rapid eGFR decline", 20)])]),
      plainCell([para([reg("Withhold ARB; urgent nephrology consult", 20)])]),
    ]),
    row([
      plainCell([para([bold("Suspected renovascular hypertension", 20)])], LGREY),
      plainCell([para([reg("Duplex renal ultrasound + nephrology/radiology referral; hold ARB pending investigation", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Confirmed pregnancy", 20)])]),
      plainCell([para([bold("Immediate switch to methyldopa, labetalol, or nifedipine (extended-release); urgent obstetric review", 20, RED)])]),
    ]),
    row([
      plainCell([para([bold("Hypertensive urgency (SBP ≥180 / DBP ≥120, no organ damage)", 20)])], LGREY),
      plainCell([para([reg("Oral antihypertensive dose increase (or short-acting amlodipine/captopril); repeat BP at 1–2 h; aim for 25% reduction in 24 h, not rapid normalisation", 20)])], LGREY),
    ]),
    row([
      plainCell([para([bold("Hypertensive emergency (SBP ≥180 / DBP ≥120 + acute organ damage)", 20)])]),
      plainCell([para([bold("EMERGENCY REFERRAL. IV antihypertensive therapy (labetalol, nicardipine, sodium nitroprusside); ICU monitoring; target 25% SBP reduction in 1 h", 20, RED)])]),
    ]),
    row([
      plainCell([para([bold("Angioedema", 20)])], LGREY),
      plainCell([para([bold("Discontinue immediately; emergency treatment if airway compromised; do not rechallenge with ARB", 20, RED)])], LGREY),
    ]),
  ], [3000, 6500]),
  spacer(),
];

// ── Section 10 – References ───────────────────────────────────────────────────
const sec10 = [
  hPara("10. References", HeadingLevel.HEADING_1),
  bullet("2025 AHA/ACC/AANP et al. Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circulation. 2025. PMID: 40815242"),
  bullet("2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension. Eur Heart J. 2024."),
  bullet("Harrison's Principles of Internal Medicine, 22nd Edition (2025). McGraw Hill Medical — Chapter 288 (Hypertension)."),
  bullet("Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Edition — Chapters 30, 31, 32."),
  bullet("Brenner and Rector's The Kidney, 2-Volume Set — Chapter 49 (Antihypertensive Therapy)."),
  bullet("Comprehensive Clinical Nephrology, 7th Edition — Chapter 34 (BP Classification and Thresholds)."),
  bullet("Fuster and Hurst's The Heart, 15th Edition — Chapter 5 (Elevated Blood Pressure and Hypertension)."),
  bullet("Xie M et al. Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis. Clin Cardiol. 2023 Aug. PMID: 37432701"),
  spacer(),
  para([italic("This protocol is intended as a clinical reference tool. Individual patient circumstances may require deviation from these recommendations. Always exercise clinical judgement and consult current local guidelines and the prescribing information.", 18, "777777")]),
];

// ── Assemble document ─────────────────────────────────────────────────────────
const children = [
  ...coverPage,
  ...sec1,
  ...sec2,
  ...sec3,
  ...sec4,
  ...sec5,
  ...sec6,
  ...sec7,
  ...sec8,
  ...sec9,
  ...sec10,
];

const doc = new Document({
  styles: {
    default: {
      document: {
        run: { font: "Calibri", size: 20 },
        paragraph: { spacing: { line: 276 } },
      },
    },
    paragraphStyles: [
      {
        id: "Heading1",
        name: "Heading 1",
        basedOn: "Normal",
        next: "Normal",
        run: { bold: true, size: 28, color: NAVY, font: "Calibri" },
        paragraph: {
          spacing: { before: 360, after: 120 },
          border: { bottom: { style: BorderStyle.SINGLE, size: 6, color: TEAL } },
        },
      },
      {
        id: "Heading2",
        name: "Heading 2",
        basedOn: "Normal",
        next: "Normal",
        run: { bold: true, size: 24, color: TEAL, font: "Calibri" },
        paragraph: { spacing: { before: 240, after: 80 } },
      },
    ],
  },
  sections: [
    {
      headers: {
        default: new Header({
          children: [
            new Paragraph({
              children: [
                reg("Clinical Dosing & Monitoring Protocol — Amlodipine / Valsartan", 18, "777777"),
              ],
              alignment: AlignmentType.RIGHT,
              border: { bottom: { style: BorderStyle.SINGLE, size: 4, color: "CCCCCC" } },
            }),
          ],
        }),
      },
      footers: {
        default: new Footer({
          children: [
            new Paragraph({
              children: [
                reg("Version 1.0  |  May 2026  |  Page ", 16, "999999"),
                new TextRun({ children: [PageNumber.CURRENT], size: 16, font: "Calibri", color: "999999" }),
                reg(" of ", 16, "999999"),
                new TextRun({ children: [PageNumber.TOTAL_PAGES], size: 16, font: "Calibri", color: "999999" }),
              ],
              alignment: AlignmentType.CENTER,
              border: { top: { style: BorderStyle.SINGLE, size: 4, color: "CCCCCC" } },
            }),
          ],
        }),
      },
      children,
    },
  ],
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync('/home/daytona/workspace/amlodipine-valsartan-protocol/Amlodipine_Valsartan_Protocol.docx', buffer);
  console.log('Document created successfully');
});

Running Command

cd /home/daytona/workspace/amlodipine-valsartan-protocol && node build.js 2>&1

Running Command

python3 /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/works…

Running Command

cd /home/daytona/workspace/amlodipine-valsartan-protocol && python3 /home/dayton…

Running Command

ls -lh /home/daytona/workspace/amlodipine-valsartan-protocol/Amlodipine_Valsarta…

The document is ready. Download it here:

Amlodipine Valsartan Protocol

Word Document · DOCX

Here's what the document contains across 10 sections:

Section	Content
Cover Page	Title, version, date, source references
1. Drug Overview	Mechanism of action table (CCB vs ARB), pharmacokinetics comparison, rationale for combination
2. Indications & Contraindications	Approved uses; colour-coded contraindications table (pregnancy, bilateral RAS, dual RAAS blockade, etc.)
3. Dosing Protocol	All 4 Exforge® tablet strengths; standard adult initiation/titration/maximum dose steps; special population table (elderly, CKD, hepatic impairment, pregnancy, breastfeeding, paediatric)
4. BP Targets	2025 AHA/ACC vs 2024 ESC targets by patient population
5. Monitoring Protocol	Baseline assessment checklist; follow-up schedule (2 weeks → 6 months → annual); critical lab thresholds with specific action triggers
6. Adverse Effects	10 adverse effects with drug attribution, frequency, and management
7. Drug Interactions	10 interactions colour-coded by severity (contraindicated / major / moderate)
8. Patient Counselling	Administration, lifestyle modifications (DASH, sodium, exercise, alcohol, smoking), safety warnings
9. Escalation / Referral	8 clinical scenarios with specific actions including hypertensive emergency
10. References	Guideline + textbook sources with PMIDs

Which is best to take this medicine at night or morning and with food or without food

Finding Sources

Searching PubMed

"amlodipine" AND "chronotherapy" AND "evening" AND "morning"

Searching the Web

amlodipine valsartan best time to take morning or night food effect absorption evidence

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC8030911

Searching PubMed

"antihypertensive" AND "bedtime" AND "morning" AND "chronotherapy"

Reading Article

PMID: 40251431

Reading Article

PMID: 40632538

Excellent - very fresh, high-quality evidence. Here's a clear, evidence-based answer:

Morning or Night? With Food or Without?

Short Answer

Evening/bedtime is slightly better, but morning works fine too. The most important rule is consistency - take it at the same time every day. Food does not matter for amlodipine, but valsartan is best taken on an empty stomach or consistently with food.

Timing: Morning vs. Evening

The Evidence

Amlodipine (CCB):

Its extremely long half-life (30-50 hours) means it stays in the blood far beyond 24 hours. Because of this, the time of day has minimal impact on its 24-hour BP control. Multiple studies confirm morning or evening dosing give equivalent results for amlodipine alone.

Valsartan (ARB):

Has a shorter half-life (6-9 hours). Previous studies suggested bedtime dosing may reduce nocturnal BP slightly more than morning dosing (by about 3 mmHg).

For the Combination (Valsartan + Amlodipine):

A randomized crossover trial (PMC8030911) compared morning vs. bedtime dosing of valsartan/amlodipine 80/5 mg directly and found morning administration was non-inferior to bedtime for nocturnal BP control. Both timings worked equally well.

However, a more recent and larger trial, the OMAN RCT (PMID 40632538, JAMA Network Open, 2025) — 720 patients across 15 hospitals — compared morning vs. bedtime dosing of an ARB/CCB combination (olmesartan/amlodipine) and found:

Bedtime dosing reduced nighttime systolic BP by an extra 3.0 mmHg more than morning dosing
Better nocturnal BP control rate: 79% vs. 70% (bedtime vs. morning)
Improved circadian BP rhythm (dipping pattern)
No increased risk of nocturnal hypotension
No difference in daytime or 24-hour BP

A 2025 meta-analysis of 56 RCTs (PMID 40251431) confirmed that CCB-based regimens in particular showed the clearest benefit from bedtime chronotherapy.

Bottom Line on Timing

Scenario	Recommendation
General preference	Evening/bedtime (6-10 PM) — modest but real benefit for nocturnal BP
If side effects at night (dizziness, hypotension)	Morning is equally acceptable
Most important rule	Same time every day - consistency beats "perfect" timing
Why nocturnal BP matters	High nighttime BP ("non-dipping pattern") is an independent risk factor for stroke and heart attack, often undertreated

Food: Does It Matter?

Drug	Effect of Food	Recommendation
Amlodipine	No significant effect on absorption	Take with or without food - your choice
Valsartan	Food decreases absorption by ~40% (peak plasma levels reduced)	Best taken on an empty stomach (or consistently the same way each day)

Since the combination contains valsartan, ideally take it 30-60 minutes before a meal, or at least 2 hours after eating. If this is inconvenient, pick a consistent approach (always with food, or always without) - consistency matters more than perfection, because valsartan's BP-lowering is dose-adjusted to what you take consistently.

- Goodman & Gilman's Pharmacological Basis of Therapeutics; OMAN RCT (JAMA Network Open 2025); PMC8030911

Practical Recommendation

Take amlodipine/valsartan (Exforge) once daily at bedtime, on an empty stomach (e.g. 9 PM, 2+ hours after dinner). This gives the best nocturnal BP control, takes advantage of amlodipine's peak at 6-12 hours (overnight), and avoids the food interaction with valsartan. If you experience dizziness when standing at night, switch to morning and discuss with your doctor.

If I take 30 minutes before dinner then

Taking it 30 minutes before dinner is actually a reasonable approach - here's why:

30 Minutes Before Dinner

For valsartan: The concern with food is that a large meal reduces valsartan's peak absorption by ~40%. Taking it 30 minutes before means it starts absorbing on an empty stomach, gets a head start, and by the time food arrives the bulk of early absorption has already begun. This is better than taking it mid-meal or right after a heavy meal.

For amlodipine: Food has no effect at all, so timing around meals is irrelevant for this component.

Is It Good Enough?

Scenario	Valsartan Absorption
Fasting (2+ hours after eating)	Best - full absorption
30 min before a light/moderate meal	Good - acceptable in practice
30 min before a heavy/fatty meal	Moderate - some reduction likely
With or right after a meal	Least optimal

Practical Verdict

Yes, 30 minutes before dinner works well - especially if dinner is a normal-sized meal rather than a very heavy one. Many patients find this easy to remember ("take it when you start preparing dinner") and the consistency of a pre-dinner habit is more valuable long-term than occasionally forgetting a fasting dose.

The only scenario where you'd want to reconsider is if your dinner is consistently very large or high-fat, in which case moving the dose to bedtime (2+ hours after eating) would give more predictable absorption.

Key point: Whatever routine you choose, stick with it every day. Your doctor will adjust your dose based on your BP readings on your consistent routine - switching back and forth between fasting and fed conditions is what actually causes unpredictable BP control.

22 may at night before bed 160/110 ‎23 may at night before meal 175/115 ‎24 may at afternoon 170/110 ‎24 may at night before meal 180/120 ‎

These readings are concerning and need to be addressed clearly.

Your BP Readings

Date & Time	SBP	DBP	Category
22 May – night	160	110	Stage 2 / Severe
23 May – before meal	175	115	Stage 2 / Severe
24 May – afternoon	170	110	Stage 2 / Severe
24 May – night (today)	180	120	Hypertensive Urgency

This Is a Hypertensive Urgency

Tonight's reading of 180/120 mmHg meets the threshold for hypertensive urgency (SBP ≥180 and/or DBP ≥120 mmHg).

More importantly, your BP has been trending upward over 3 days despite presumably being on medication. This is not a good sign.

What You Need to Do Right Now

Contact your doctor or go to an emergency department tonight.

Do not wait until tomorrow. The reason urgency needs same-day medical assessment is to check whether there is any organ damage happening silently - this is what separates urgency (no organ damage) from emergency (organ damage in progress).

Your doctor will check for:

Headache, visual changes, chest pain, shortness of breath, confusion - these suggest hypertensive emergency, which needs IV treatment in ICU
Urine (protein, blood) - kidney involvement
ECG - heart strain
If none of these are present, it is urgency and can be managed with oral medications

Warning Signs - Go to ER Immediately If You Have Any of These

Severe headache or head pounding
Blurred vision or seeing spots
Chest pain or tightness
Shortness of breath
Confusion or difficulty speaking
Nausea/vomiting
Nosebleed that won't stop
Weakness or numbness in face/arm/leg

Do NOT

Do not take an extra dose of your medication on your own without medical advice
Do not lie down and hope it resolves
Do not delay if any warning symptoms appear

The bottom line: a BP of 180/120 that has been rising for 3 days requires medical evaluation today. Please contact your doctor or go to the nearest emergency department now.

I haven't start any medication yet for bp

This makes the situation more urgent, not less.

You Are at 180/120 With Zero Medication on Board

This means your BP is reaching hypertensive urgency levels completely untreated. There is no medication causing a temporary spike - this is your baseline state right now.

You Need to Go to the Doctor or ER Tonight

Not tomorrow. Tonight.

At 180/120 with a rising trend over 3 days and no treatment started, the immediate priorities are:

Rule out hypertensive emergency - check if organs are already being damaged
Start medication today - this level of BP cannot wait for a scheduled appointment next week
Find out why - newly discovered hypertension at this level sometimes has a secondary cause (kidney disease, hormonal problem, etc.) that needs to be identified

What the Doctor Will Do

Check your symptoms (headache, vision, chest, breathing)
Blood tests - kidney function, electrolytes, blood count
Urine test - protein or blood in urine signals kidney damage
ECG - heart strain from high BP
Eye exam possibly - retinal changes from hypertensive damage
Start you on antihypertensive medication immediately

While You Wait / On Your Way

Sit or lie quietly - avoid exertion
No caffeine, no smoking right now
Breathe slowly and calmly - anxiety raises BP further
If you have any of these symptoms, call emergency services (ambulance) rather than driving yourself:
- Chest pain
- Difficulty breathing
- Sudden severe headache
- Vision changes
- Confusion or slurred speech
- Weakness in face, arm, or leg

The Core Message

180/120 mmHg, untreated, rising over 3 days = go to hospital now.

This is not something to monitor at home and reassess tomorrow. At this BP level, every hour without treatment carries real risk of stroke, heart attack, or kidney damage. Please go tonight.

This is a shared conversation. Sign in to Orris to start your own chat.